

1/27

Intai Technology TWSE: 4163


February 2014

RF Microwave Precision Hardware Medical Devices



Table of Contents

- 1. Company overview
- 2. Product categories
- 3. Medical devices prospect
- 4. Future projects
- **5. Financial highlights**





Company overview

Product categories

Medical devices prospect

Future projects

Financial highlights

Major shareholders and management profile

	Shareholding (%)
Founder - Mr. Lin and family	22.0
GM - Mr. Chung and family	10.0
Chairman &CEO - Mr. Tsai	2.3
VP - Mr. Lin and CFO - Ms Su	5.8
Chinatrust Venture Capital	3.2
VP - Mr. Sun	1.5
Major shareholder Total	44.8



- ·Chairman&CEO: Simon Tsai •30 years in the metalworking industry •18 years with Intai
- •BS of National Taiwan **University of Science** and Technology



•CFO: Lily Su •19 years with Intai •EMBA of **National Chung Hsing University**



- VP of Medical BU: Mark Wu
- 11 years in the metalworking and **Bike assembly** industry
- 8 years with Intai
- BS of National **Chung Hsing University of Soil** and Environmental Science



- GM: John Chung
- •40 years in the
- metalworking industry •25 years with Intai
- BS of Air Force Institute of Technology (Taiwan)



- CSO: Paul Lin
- Founder of Intai
- •40 years in the
- metalworking industry
- BS from National Taipei University of Technology



Patrick Lin

industry

· 30 years in the

metalworking

25 years with Intai

MBA of Soochow

University China

- VP of Fastener BU: VP of Switch BU: **Richard Sun**
 - Director of Switch **Dept at Teledyne**
 - · 40 years in the
 - microwave switches industry
 - 10 years with Intai
 - MS of University of California



Precision metal works at the core

Medical Devices





00000

Radio Frequency & Microwave Switches



1 prover in the

Applications





Precision Fasteners










Total sales by product category

Total sales breakdown by product category





Intai's competitive advantages

- Decades of experience combining capabilities across medical and metalworking sectors and acquired international certifications
- Client relationships spanning over 20 years
- Innovative and non-conventional metal-working techniques to produce complex precision shapes
- One-third in-house developed tools and equipment
- R&D capabilities with early-stage product development with customers
- Capacity optimization combining high mix, low volume with higher volume, mass value-added products
- Co-development with Industrial Technology Research Institute (ITRI)



Vision and plan

OEM

- Double market share in our major client to 5% within 3 years
- Establish relationship with other subsidiaries within our major client's group to increase 3 more accounts within 3 years

ODM

- Explore more opportunities in product co-design/co-development with clients based on our past successful experience
- Further leverage current capability in innovative product design and development

OBM

- Continue to develop own-brand dental and orthopedic implants launched in 2013
- China/SE Asia sales to account for 10% of revenues within 3 years






1.Medical component/assembly

- Major metal components supplier for global leading endoscopic surgery instrument brand (half of Intai's 2012 total sales)
- One of few qualified suppliers in Asia, with most peers in the US
- Also supplier of orthopedic/dental implants and other medical components
- Over 35% blended gross margin in 2013

Intai sales in Medical component/ assembly








2.Precision Fasteners

- Standard and customized fasteners with applications in automotive, construction, aerospace, furniture industries and etc... (NT\$ mn)
- Over 20% blended gross margin in 2013
- Focus on high value-added metal components

Intai sales in Precision Fasteners












3.RF & Microwave Switches

- Customized and niche radio frequency and microwave switches with applications in automobile, wireless telecommunication (ex: aviation, mobile phone base station, military...etc)
- Major clients are top 2 players in the world
- Over 40% blended gross margin in 2013
- Capacity expansion plan by 4Q13 to cater client demand; will launch OBM products in 3Q14


Intai sales in RF/ Microwave Switches







Intai's addressable market in the global medical device industry








Global trend from open surgery to Minimally Invasive Surgery (MIS)


Intai Medical sales breakdown by application








Global MIS device market to grow 10% annually, with greater potential in emerging Asia



Source: MarketsandMarkets, MIRDC



Source: MarketandMarkets(2010), MIRDC, IEK





US\$14.5 bn market in 2011 with 6-9% projected CAGR through 2016

Unit: US\$						
Products	2009	2010	2011	2016	CAGR% (2011-2016)	
Orthobiologics	3,894.5	4,143.2	4,437.5	6,208.1	6.9	
Joint reconstruction	12,944.6	13,681.4	14,463.7	19,173.8	5.8	
Spinal devices	7,033.3	7,803.6	8,660.5	13,529.5	9.3	
Trauma fixation devices	5,183.2	5,505.3	5,845.0	7,929.7	6.3	
Arthroscopic devices	3,381.7	3,607.8	3,849.6	5,343.5	6.8	
Orthopedic accessories	2,307.7	2,355.6	2,405.1	2,678.8	2.2	
Orthopedic braces and support system	1,958.6	2,571.7	2,640.3	3,021.7	2.7	
Total	36,703.6	39,668.6	42,301.7	57,885.1	6.5	

Source: Global Orthopedics Devices Market (2011-2016)






Projects next 2 years

Own-brand dental implants

- Launched own-brand Royal Dent for dental implant products in 2013, with positive feedback from clinical sales in Taiwan
- Received Taiwan FDA, US FDA, and CE approvals. Target China FDA approval in 3Q14

Orthopedic implants

- 500,000 patients receive spine fusion surgery in the US every year
- MIS orthopedic surgery contributes to reduction of incision and recovery time
- Intai manufactures related components including screws, cage, fixation system.







Longer-term projects

Annulus Repair device

- Annulus Repair Device for Non-Fusion Spinal Reconstruction : Co-development with Taiwan's Industrial Technology Research Institute
- Removal of unwanted tissues and stitching in early treatment, with minimal scarring
- Undergoing animal testing


Thermal Injector Fusion

- The thermal injectable bone graft for spinal fusion is injected and spread out evenly in lumbar disc, while in traditional fusion surgery it's difficult to confirm whether the fusion is placed optimally
- The wound size of the thermal injectable fusion is under 1cm, while wound size of traditional MIS ranges 3-5 cm



Revenue growth

Margins






35% 28.7% 30% 25% 19.0% 18.0% 20% 19.3% 15% 11.0% 9.7% 10% 8.0% 7.3% 5% 0% 2009 2010 2011 2012

ROE and ROA

Operating cash flow & Capex







Dividend policy

	2009	2010	2011	2012
EPS (NT\$)	3.95	2.88	3.27	4.68
Cash DPS (NT\$)	2.0	1.5	2.0	3.0
Payout ratio (%)	50.6	52.2	61.1	64.0
Cash yield (%)*	-	-	3.3	2.7

* Based on share price on following year's closing before ex-dividend day.





Consolidated income statement highlights

NT\$ mn	2009	2010	2011	2012	9M13
Revenue	980	1,129	1,164	1,348	1,132
Gross Profit	321	383	349	429	426
Gross Margin (%)	32.8	33.9	30.0	31.8	37.6
Operating Profit	116	120	90	127	204
Operating Margin (%)	11.8	10.6	7.7	9.4	18.1
Income before Tax	127	99	134	206	230
Net Income	115	95	114	175	193
Net Margin (%)	11.7	8.4	9.8	13.0	17.1
EPS (NT\$)	3.89	2.88	3.23	4.69	4.81
YoY (%)	2009	2010	2011	2012	
Revenue		15.2	3.1	15.8	
Gross Profit		19.3	(8.9)	22.9	
Operating Profit		(3.4)	25.0	(41.1)	
Net Income		(17.4)	20.0	53.5	





Consolidated balance sheet highlights

NT\$ mn	2009	2010	2011	2012	9M13
Cash & cash equivalent	158	229	256	395	223
Inventories	334	297	391	377	428
Total current assets	673	766	904	949	858
Long-term investments	17	16	16	16	16
Net fixed assets	350	470	858	799	784
Total assets	1,086	1,294	1,825	1,809	1,693
Short-term borrowings	148	278	226	0	137
Total current liabilities	415	509	690	290	532
Long-term debts	146	231	343	401	0
Long-term liabilities	185	272	386	450	64
Total liabilities	599	782	1,076	740	596
Retained earnings	117	134	183	273	270
Shareholders' equity	486	512	749	1,069	1,097
Net debt/equity (%)	28	55	42	1	(Net cash)
Current ratio (X)	1.6	1.5	1.3	3.3	1.6
BVPS (NT\$)	14.7	15.5	20.2	26.6	27.3





Consolidated cash flow highlights

NT\$ mn	2009	2010A	2011	2012	9M13
Net profit	115	95	114	175	193
Depreciation & amortization	29	25	26	54	37
Change in working capital	23	40	(28)	(64)	(21)
Others	39	(67)	22	(7)	(21)
Operating cash flow	205	93	134	159	188
Capex	(42)	(139)	(255)	(204)	(37)
Change in investments	(6)	0	0	0	0
Change in other assets	(1)	(31)	(27)	204	1
Investment cash flow	(49)	(169)	(282)	0	(36)
Change in share capital	80	0	175	224	0
Net change in debt	0	214	61	(169)	(204)
Other adjustments	(138)	(66)	(55)	(74)	(121)
Financing cash flow	(58)	148	181	(19)	(324)
Free cash flow	163	(45)	(121)	(46)	151